Skip to content Skip to footer
Subscribe Now
NEWS

The NMPA Accepts The United Laboratories’ Marketing Application for IDegLira Biosimilar  

Shots:  China’s NMPA has accepted marketing registration application for insulin degludec & liraglutide injection (IDegLira), developed by TUL’s wholly owned subsidiary Zhuhai United Bio-Pharmaceutical    IDegLira is a once-daily fixed-dose combination of basal insulin degludec and the GLP-1 analogue liraglutide for type 2 diabetes, designed to provide complementary glucose-lowering effects while simplifying treatment   Through complementary and…
September 24, 2026

Read more

Insights+ Key Biosimilars Events of January 2024
INSIGHTS+

Insights+ Key Biosimilars Events of January 2024

Shots:   Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency    Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients    During January, Coherus BioSciences divested its Ophthalmology Franchise that included Cimerli and Glenmark launched…
February 7, 2024

Read more

Insights+ Key Biosimilars Events of September 2023
INSIGHTS+

Insights+ Key Biosimilars Events of September 2023

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients During the month of September, Sandoz entered into a development and commercialization agreement…
October 4, 2023

Read more